Partially replacing cyclophosphamide with bendamustine in combination with cyclosporine A improves survival and reduces xenogeneic graft-versus-host-disease

Partially replacing cyclophosphamide with bendamustine in combination with cyclosporine A improves survival and reduces xenogeneic graft-versus-host-disease

IntroductionThe use of allogeneic hematopoietic cell transplantation (allo-HCT) for treating hematological disorders is increasing, but the development of graft-versus-host disease (GvHD) remains a major cause of morbidity and mortality. The use of post-transplant cyclophosphamide (CY) has significa...

Full description

Bibliographic Details
Main Authors: Kristy E. Gilman, Megan J. Cracchiolo, Andrew P. Matiatos, Dan W. Davini, Richard J. Simpson, Emmanuel Katsanis
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-01-01
Series:Frontiers in Immunology
Subjects:
allogeneic hematopoietic cell transplantation
bendamustine
cyclophosphamide
xenogeneic
graft-versus-host disease
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.1045710/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.1045710/full

Similar Items